The National Heart, Lung, and Blood Institute working group acknowledges that pathophysiological, epidemiological, and genetic studies provide strong evidence that Lp(a) is a causal mediator of both ASCVD and CAVD [94]. This evidence concerns the gene LPA and congenital bilateral aplasia of vas deferens from CFTR mutation.